Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer.
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
The study included a total of 183 patients with genitourinary cancers.
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.
Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based chemotherapy.
The network meta-analysis aimed to compare various combinations of treatment options to determine the safest and most effective management strategy for mCSPC.
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.